The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [Tc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [Tc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer.

Purpose: Radiolabeled PSMA-ligands play a major role in today's nuclear medicine. Since approval of [Lu]Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of Lu became bottleneck of supply due to the high demand. Recently, a theranostic PSMA-ligand, PSMA-GCK01, was developed which can be labeled either diagnostically with Tc or therapeutically with Re with both nuclides available from well-known generator systems.